血管性认知障碍患者血清BACE1、sRAGE水平变化

目的探讨血清淀粉蛋白前B位分解酶1（BACE1）、糖基化终末产物受体可溶性片段（sRAGE）在血管性认知障碍患者中的变化及其临床意义。方法选取2012年1月至12月收治的89例缺血性脑卒中患者，其中无认知障碍的患者（脑卒中组）26例，血管性轻度认知障碍非痴呆组50例，血管性痴呆组13例。另选20例正常健康人作为对照组。检测并比较各组血清BACE1、sRAGE水平。结果脑卒中组与对照组血清sRAGE、BACE1水平相近，差异均无统计学意义（P均〉0．05）。与脑卒中组和对照组相比，血管性轻度认知障碍组、血管性痴呆组血清sRAGE水平明显下降（P均〈0．05），血清BACEl水平明显增高（P均〈0．05）。结论BACE1、sRAGE在血管性认知障碍患者中早期就有变化，可作为卒中后认知障碍早期诊断的分子生物学标记物。

Changes of serum BACE1 and sRAGE levels in patients with vascular cognitive impairment

Objective To study the changes of 13-site APP-Cleaving Enzyme 1 （ BACE1 ） and soluble fragment of receptor for advanced glycation end products （sRAGE） in patients with vascular cognitive impairment. Methods Eighty-nine patients with ischemic cerebral stroke from January 2012 to December 2012 were enrolled in this study. Of the 89 patients, 26 had not cognitive impairment （ cerebral stroke group）, 50 had mild vascular cognitive impairment （vascular mild cognitive impairment group）, 13 had vascular dementia （vascular dementia group）. Twenty normal healthy subjects were served as control group. Serum BACE1 and sRAGE were detected by double sandwich enzyme-linked immunosorbent method in all participants. Result The levels of BACE1 and sRAGE were similar between cerebral stroke group and control group （ all P 〉 0. 05 ）. Compared with cerebral stroke group and control group, the sRAGE levels in vascular mild cognitive impairment group and vascular dementia group decreased respectively （all P 〈0.05） ,while the BACE1 levels increased respectively （all P 〈 0.05 ）. Conclusions The levels of BACE1 and sRAGE have already changed in patients with early vascular cognitive impairment, therefore they may be served as the biomarkers for early diagnosing of post - stroke cognitive impairment.